Dr. Raffaele Baffa M.D., Ph.D. is the Chief Medical Officer and Exec. VP of R&D at Alaunos Therapeutics Inc.
As the Chief Medical Officer and Exec. VP of R&D of Alaunos Therapeutics Inc, the total compensation of Dr D at Alaunos Therapeutics Inc is $242,834. There are 8 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.
Dr D is 60, he's been the Chief Medical Officer and Exec. VP of R&D of Alaunos Therapeutics Inc since . There are 3 older and 13 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
Raffaele's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk y Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: